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Introduction
The Notch signaling pathway is of central importance for the regu-
lation of developmental processes by mediating direct cell-to-cell 
communication between cells in a wide variety of developmental 
contexts in different species (Campos-Ortega, 1994; Muskavitch, 
1994; Blaumueller and Artavanis-Tsakonas, 1997; Gridley, 1997; 
Artavanis-Tsakonas et al., 1999). Products of the Notch, Delta, 
and Serrate (called Jagged in mammals) genes are crucial for this 
direct interaction between neighboring cells. Notch genes encode 
large transmembrane proteins that, at the extracellular surface of a 
cell, act as receptors for proteins encoded by the Delta and Serrate 
genes. Like Notch, Delta and Serrate are transmembrane ligands 
with a variable number of EGF-like repeats in their extracellular 
domains (Wharton et al., 1985; Vässin et al., 1987; Thomas et al., 
1991). In addition, the Delta and Serrate proteins contain in their 
extracellular portion a conserved cysteine-rich region known as 
DSL domain (Delta, Serrate, lag-2), which is essential for ligand 
binding (Shimizu et al., 1999, 2000). Generally, vertebrates con-
tain several copies of genes encoding particular Notch pathway 
components. In the mouse, there are four genes encoding Notch 
proteins, three genes coding for Delta (Dll1, Dll3, and Dll4), and 
two for Serrate (Jagged1 and Jagged2) proteins, respectively. Little 
is known about how these ligands interact with various Notch 
receptors in vivo, and whether the signals elicited by these inter-
actions are quantitatively or qualitatively different.
Studies in zebrafi  sh, Xenopus, chicken, and mouse embryos 
have demonstrated an essential requirement for Notch signaling 
during somite formation and patterning. In mice, mutational ana-
lyses have shown that two ligands, Dll1 (Hrabe de Angelis et al., 
1997) and Dll3 (Kusumi et al., 1998; Dunwoodie et al., 2002), are 
essential for normal somite formation and patterning. Dll1 and 
Dll3 are coexpressed throughout most of the presomitic meso-
derm (PSM) and differentially expressed in the anterior and pos-
terior compartments of newly formed somites (Dunwoodie et al., 
1997). However, despite the overlapping mRNA expression in the 
PSM, loss of Dll1 or Dll3 function leads to clearly distinct pheno-
types. Somites in Dll1 mutant embryos lack any detectable anterior–
posterior (A-P) polarity, as indicated by the loss of Uncx4.1 
expression. Loss of segment polarity is already evident in the 
anterior PSM. Somites are not fully epithelialized, their borders 
are not maintained, and Lfng expression in the PSM is down-
regulated to barely detectable levels (Hrabe de Angelis et al., 1997; 
Morales et al., 2002). In contrast, null alleles of Dll3 (Kusumi 
et al., 1998; Dunwoodie et al., 2002) disrupt somite polarity such 
that Uncx4.1 expression appears randomized throughout somites 
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he Notch ligands Dll1 and Dll3 are coexpressed in 
the presomitic mesoderm of mouse embryos. Despite 
their coexpression, mutations in Dll1 and Dll3 cause 
strikingly different defects. To determine if there is any func-
tional equivalence, we replaced Dll1 with Dll3 in mice. Dll3 
does not compensate for Dll1; DLL1 activates Notch in 
Drosophila wing discs, but DLL3 does not. We do not ob-
serve evidence for antagonism between DLL1 and DLL3, or 
repression of Notch activity in mice or Drosophila. In vitro 
analyses show that differences in various domains of DLL1 
and DLL3 individually contribute to their biochemical non-
equivalence. In contrast to endogenous DLL1 located on the 
surface of presomitic mesoderm cells, we ﬁ  nd endogenous 
DLL3 predominantly in the Golgi apparatus. Our data 
demonstrate distinct in vivo functions for DLL1 and DLL3. 
They suggest that DLL3 does not antagonize DLL1 in the pre-
somitic mesoderm and warrant further analyses of poten-
tial physiological functions of DLL3 in the Golgi network.
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instead of being restricted to the posterior compartment, and Lfng 
expression is readily detected, although transcriptional oscillation 
appears abnormal (Dunwoodie et al., 2002; Kusumi et al., 2004). 
These qualitatively different phenotypes suggest that these lig-
ands are not functionally equivalent in vivo. Support for this no-
tion comes from a recent study that showed that DLL3 cannot 
activate Notch in vitro and suggested that DLL3 acts as an antago-
nist to DLL1 on the cell surface (Ladi et al., 2005).
Here, we demonstrate that the DLL1 and DLL3 proteins 
are not equivalent in mouse embryos. Replacement of the Notch 
ligand Dll1 with Dll3 in mice resulted in a phenotype indistin-
guishable from the Dll1-null phenotype, although Dll3 expressed 
from the Dll1 locus is functional. Similarly, in transgenic fl  ies, 
Dll1, as well as Dll4, acted as a bona fi  de activator of Drosophila 
melanogaster Notch in the wing imaginal disc, whereas Dll3 
did not. Changing the ratios of Dll1and Dll3 in vivo in mice or 
ectopic expression in flies did not provide genetic evidence 
for antagonism between DLL1 and DLL3 or repression of Notch 
activity by DLL3. Also, NICD was not up-regulated in the PSM 
of embryos lacking DLL3. In vitro analyses using chimeric 
DLL1-DLL3 proteins showed that differences in the DSL do-
mains, EGF repeats, and intracellular domains (ICDs), respec-
tively, contribute to their biochemical nonequivalence. In contrast 
to DLL1, DLL3 protein was predominantly detected inside the 
cell, including in the Golgi network. Our data prove that DLL1 
and DLL3 have distinct functions in vivo; under physiological 
conditions, the proteins are differentially localized in the cell, 
and DLL3 might not act simply by antagonizing DLL1.
Results
Generation of Dll1 and Dll3 knockin alleles
To express the Dll3 coding region from the Dll1 locus and simul-
taneously eliminate Dll1 function, we generated mice that carried 
a chimeric Dll3 “minigene” fused in frame into the ATG of 
the endogenous Dll1 gene, analogous to the Dll1
lacZ-null allele 
generated previously (Hrabe de Angelis et al., 1997). In the Dll3 
minigene, the Dll3 coding sequence, either with or without a 
C-terminal HA tag, was linked at the 3′ end to genomic sequences 
of the Dll1 gene containing exons 9–11 (Fig. 1 A). After process-
ing of the primary transcript, the Dll3 coding sequence is thus 
fl  anked by the Dll1 5′ and 3′ UTRs, which should generate Dll3 
transcripts with stability and properties similar to those of the gen-
uine Dll1 mRNA. As a control to ensure that this structural altera-
tion at the Dll1 locus had no adverse effects on expression of the 
Dll3 minigene, we also generated mice that carried an analogous 
minigene version of Dll1 targeted to the Dll1 locus (Fig. 1 A).
The Dll3 knockin (Dll1
Dll3HAki and Dll1
Dll3ki) and the Dll1 
control alleles (Dll1
Dll1ki) were passed through the germ line 
of ZP3::Cre females (de Vries et al., 2000) to remove the fl  oxed 
neo cassette that was included in the targeting vectors (Fig. 1 A). 
Heterozygous mice carrying either knockin allele did not show 
obvious external phenotypes or obvious malformations of the 
axial skeleton (Fig. 2 A, a–c; and not depicted). Likewise, homo-
zygous mice carrying the Dll1
Dll1ki allele were viable and fertile 
without any apparent phenotype (Fig. 2 A, m-o; and not depicted), 
indicating that the Dll1 minigene was suffi  cient to compensate 
for the disrupted endogenous gene. In contrast, no homozygous 
Dll1
Dll3HAki or Dll1
Dll3ki offspring were obtained from matings of 
heterozygous Dll1
Dll3HAki or Dll1
Dll3ki mice, respectively, although 
the HA-tagged DLL3 protein was expressed (Fig. 1 C). This sug-
gested that Dll3 was unable to functionally replace Dll1.
DLL3 generated from the knockin alleles 
is functional
To test whether the Dll3 and Dll3HA cDNAs expressed from 
the Dll1 locus generate functional proteins, we crossed hetero-
zygous Dll1
Dll3ki and Dll1
Dll3HAki mice, respectively, to mice car-
rying a null mutation of Dll3, Dll3
pu (Kusumi et al., 1998). Dll3
pu 
disrupts A-P somite patterning and leads to severe malforma-
tions of the axial skeleton (Fig. 2 A, d–f). Compound heterozy-
gous mice carrying one copy of the Dll1
lacZ and the Dll3
pu-null 
Figure 1.  Generation of Dll1
Dll3Haki,  Dll1
Dll3ki, 
and Dll1
Dll1ki mice. (A) Targeting strategy for in-
troduction of Dll3 and Dll1 into the Dll1 locus. 
White and black boxes indicate noncoding 
and coding regions, respectively. The blue box 
indicates a Dll1, Dll3, or Dll3HA cDNA, respec-
tively. DT, diphtheria toxin A chain. (B) E10.5 
embryos. (C) Veriﬁ  cation of Dll3HA expression 
by Western blot analysis with anti-HA anti-
bodies. Lysates of CHO cells transfected with 
Dll3HA cDNA (a) and of wild type (b) and 
Dll1
Dll3HA/Dll3HA (c) E9.5 embryos. Embryo lysates 
represent half of one embryo, respectively.NONEQUIVALENCE OF DLL1 AND DLL3 • GEFFERS ET AL. 467
allele, respectively, i.e., mice that have only one functional copy 
of either gene are normal (unpublished data). Mice that are ho-
mozygous mutant for Dll3
pu but are heteroallelic for the Dll1 
wild type and the Dll1
Dll3 knockin alleles also have one func-
tional copy of Dll1 and one copy of Dll3 or Dll3HA expressed 
from the Dll1 locus. Therefore, we reasoned that functional 
DLL3 protein generated from the knockin alleles should at least 
partially rescue the phenotype of homozygous Dll3
pu mice. 
Indeed, homozygous Dll3
pu mice that carried one copy of the 
Dll1
Dll3ki or Dll1
Dll3HAki allele (n = 2 and 4, respectively) were 
normal or showed only subtle defects of the vertebral column 
(Fig. 2 A, g–i; and not depicted), in contrast to homozygous Dll3
pu 
mice (Fig. 2 A, d–f). Consistent with normal axial skeleton 
development, cyclic Lfng expression and stripy expression of 
Uncx4.1 was restored in Dll1
Dll3HAki/+; Dll3
pu/pu embryos (Fig. 
2 B, m–o). This unambiguously demonstrated that the Dll3 and 
Dll3HA cDNA expressed from the Dll1 locus generated fully 
functional DLL3 protein and indicates that the C-terminal HA 
tag does not interfere with the physiological functions of DLL3.
DLL3 does not rescue the loss 
of DLL1 in vivo
To address whether the DLL3 protein can rescue some aspects of 
the loss of DLL1 function, we analyzed homozygous Dll1
Dll3ki 
and Dll1
Dll3HAki embryos. Embryos homozygous for the Dll1
lacZ-
null allele die around embryonic day (E) 11.5 and can be readily 
identifi  ed at E10.5 by large hemorrhages (Fig. 1 B b). Homozygous 
embryos with either knockin allele were virtually identical to null 
mutants (Fig. 1 B, c and d), and A-P somite patterning, as well as 
cyclic gene expression, was similarly disrupted in homozygous 
Dll1
Dll3HAki and Dll1
lacZ embryos (Fig. 2 B, compare j–l with p–r), 
indicating that Dll3 cannot functionally replace Dll1 in vivo. 
Collectively, our analyses demonstrate unequivocally that the 
DLL1 and DLL3 proteins are biochemically not equivalent and 
have divergent functions in vivo.
DLL3 does not repress DLL1-mediated 
Notch activation in vivo
Based on in vitro experiments and overexpression in Xenopus 
embryos, it was suggested that Dll3 functions as an inhibitor 
of Notch signaling in a cell-autonomous manner (Ladi et al., 
2005). If this refl  ects the physiological role of Dll3 in the PSM 
of mouse embryos, where Dll1 and Dll3 are coexpressed in the 
majority of cells (Dunwoodie et al., 1997), changes in the ratio 
of Dll3 to Dll1 might lead to either reduced or enhanced Notch 
signaling and defects in somite patterning and axial skeleton 
development. Indeed, about one third of mice heterozygous for 
the Dll1-null allele showed defects in individual vertebrae, such 
Figure 2.  Phenotypes and somite patterning 
of embryos with various Dll1 and Dll3 allele 
combinations.  (A) Embryo appearance (top) 
and skeletal preparations (bottom) of E18.5 
embryos with the genotypes indicated on top. 
Dll1
Dll3HA/+ embryos (a–c) have an essentially 
normal axial skeleton despite an increased 
gene dosage ratio of Dll3 to Dll1. Skeletal de-
fects of homozygous Dll3-null mutants (d–f) are 
rescued by Dll3HA expressed from the Dll1 
locus (g–i) except for minor residual defects 
(i, arrowheads). Increased gene dosage ratio 
of Dll3 to Dll1 does not enhance a hypomorphic 
Dll1 phenotype (compare p–r with s–u). Note 
that modiﬁ   cation of the Dll1 locus does not 
lead to any phenotypic alterations in the skele-
ton (m–o). (B) A-P somite patterning at E9.5 in-
dicated by Uncx4.1 expression and dynamic 
Lfng expression patterns are indistinguishable 
in wild-type (a–c) and Dll1
Dll3HA/+ embryos (g–i). 
Abnormal expression of Uncx4.1 and Lfng in 
homozygous Dll3
pu-null mutants (d–f) is restored 
by Dll3HA expressed from the Dll1 locus (m–o) 
except for minor irregularities of Uncx4.1 ex-
pression (m, arrowhead). Expression of Dll3HA 
instead of Dll1 (j–l) does not rescue the patterning 
defects of Dll1-null mutants (p–r).JCB • VOLUME 178 • NUMBER 3 • 2007  468
as minor fusions or reduction of laminae, split vertebral bodies, 
and reduced pedicles (Cordes et al., 2004). This indicates that 
somite patterning is sensitive to Dll1 dosage (i.e., Notch activity) 
and raises the possibility that the increased gene dosage ratio 
of Dll3/Dll1 (2:1) in Dll1
lacZ heterozygotes contributes to the 
haploinsuffi  ciency phenotype. We therefore analyzed whether 
penetrance and expressivity of axial skeleton defects are in-
creased in Dll1
Dll3HAki embryos, which carry three copies of Dll3 
but only one copy of Dll1, and thus have a Dll3/Dll1 ratio of 
3:1. In 10 out of 28 Dll1
Dll3HAki skeletons, we found minor verte-
bral malformations similar to those observed in Dll1
lacZ hetero-
zygotes (unpublished data), indicating that the increase of 
Dll3 dose did not enhance expressivity or penetrance of defects 
found in Dll1
lacZ heterozygotes. In addition, we made use of the 
Dll1
Dll1ki allele that still contained the neo cassette. The pres-
ence of the neo cassette in the Dll1
Dll1ki allele (Dll1
Dll1ki+neo) 
attenuates Dll1 expression and generates a hypomorphic Dll1 
allele that is lethal at birth in homozygotes (Schuster-Gossler 
et al., 2007). Heterozygous Dll1
lacZ mice, which have only one 
functional copy of Dll1, and thus most likely half the level of 
Dll1 mRNA and protein, survive. This suggests that total DLL1 
protein in homozygous Dll1
Dll1ki+neo hypomorphs is below this 
level, and one hypomorphic Dll1
Dll1ki+neo allele thus generates 
less than half of one wild-type allele (i.e., <25% of the total 
amount in wild type). We compared the phenotypes of mice that 
were heteroallelic for the hypomorphic and the null allele 
(Dll1
Dll1ki+neo/lacZ; <25% Dll1; two copies of Dll3) with mice 
heteroallelic for the hypomorphic and the Dll3 knockin allele 
(Dll 
Dll1ki/Dll3HAki; <25% Dll1; three copies of Dll3) and observed 
no obvious enhancement of the phenotype (Fig. 2 A, compare 
p–r with s–u). Thus, over the range of gene doses that we tested, 
we obtained no genetic evidence for antagonism of Dll1 and 
Dll3 during somitogenesis under physiological conditions.
To address more directly how DLL3 affects Notch activa-
tion in vivo, we analyzed the formation of the activated ICD of 
Notch1, NICD, in mouse embryos by immunohistochemistry. 
In wild-type embryos, Notch1 is activated in a sharp band in the 
anterior PSM, and posterior in variable patterns that refl  ect 
cyclic Notch activity (Fig. 3, A–C; Morimoto et al., 2005). Loss 
of DLL1 function abolishes formation of NICD in the PSM 
(n = 4; Fig. 3 D and not depicted; Morimoto et al., 2005), indicating 
that DLL1 is the major activator of Notch1 in the PSM. If DLL3 
acts as an antagonist of DLL1, one would expect increased 
levels or expression of activated Notch1 throughout the PSM in 
Dll3 mutants, similar to embryos without Lfng function (Morimoto 
et al., 2005). In embryos lacking DLL3 (n = 14), NICD was 
detected in a fuzzy stripe in the anterior PSM and at the posterior 
end, but not throughout the PSM, and levels appeared reduced 
rather than increased (Fig. 3, E–G; and not depicted).
DLL1 and DLL4, but not DLL3, activates 
Notch in D. melanogaster
To further analyze the activities of Dll1 and Dll3 in vivo, we 
generated transgenic fl  ies carrying UAS constructs of both Dll 
genes and expressed them with help of the Gal4 system during 
wing development using ptcGal4. The activity of Dll1 and Dll3 was 
monitored by analyzing the activation of the Notch target Wg. 
During wing development, Wg is expressed in a stripe of cells 
along the dorsoventral boundary under control of the Notch 
pathway (Klein, 2001). Expression of D. melanogaster Dl with 
ptcGal4 induces ectopic Wg expression along the A-P boundary 
(Doherty et al., 1996) and inhibited Notch activation in the 
region of highest Dl expression (Fig. 4, B and C, arrowheads), 
consistent with the known inhibition of Notch by coexpression 
of high levels of Dl (Doherty et al., 1996). Similarly, Dll1fl  ag ex-
pression induced Wg along the A-P boundary (Fig. 4, D and E), 
indicating that the mouse DLL1 protein can activate D. melano-
gaster Notch in imaginal discs in vivo. This was also observed 
in the absence of endogenous Dl (unpublished data). Likewise, 
DLL4, another mammalian ligand known to activate Notch (Iso 
et al., 2006; Diez et al., 2007), induced Wg expression (Fig. 4, 
F and G), suggesting that mammalian DSL ligands that activate 
mammalian Notch in general can activate the D. melanogaster 
Notch receptor. In contrast, Wg expression was not induced in 
wing discs expressing Dll3 or Dll3fl  ag (fi  ve independent lines 
tested for each construct; Fig. 4, H and I; and not depicted), con-
sistent with the inability of Dll3 to substitute for Dll1 in mice. 
In addition, a chimeric DLL1-DLL3 ligand that did not acti-
vate mammalian Notch (Fig. 5, construct A; see the following 
paragraph) did not activate D. melanogaster Notch in the wing 
disc (Fig. 4, J and K), supporting the idea that the inability of 
DLL3 to activate D. melanogaster Notch does not simply refl  ect 
species differences, although formally we cannot exclude this 
possibility. Dll3fl  ag did not affect the normal expression of Wg 
induced along the dorsoventral border by endogenous Dl and Ser 
in the ptc domain overlapping with the dorsoventral border (Fig. 4, 
H and I, arrowheads), indicating that expression of Dll3 does 
not block Notch activation by the endogenous ligands. Identical 
results were obtained with HA-tagged or untagged versions of 
Dll1 and Dll3 (unpublished data).
DLL1 domains required 
for Notch activation
The DLL1 and DLL3 proteins show considerable differences in 
their amino acid sequences. Compared with DLL1, the DLL3 
Figure 3.  NICD expression in the PSM of Dll3 mutant embryos. Whole-
mount immunohistochemistry for activated Notch 1 (NICD) readily detected 
oscillating activity in E10.5 embryo wild-type tails (A–C; n = 13). In Dll1-
null mutant tails (D), NICD was not detected in the PSM (n = 4), whereas 
in Dll3-null mutant tails (E–G), the pattern of Notch1 activity is static 
(n = 14) with no obvious up-regulation of NICD protein levels.NONEQUIVALENCE OF DLL1 AND DLL3 • GEFFERS ET AL. 469
protein has a divergent DSL domain, fewer EGF repeats, and 
altered spacing between some EGF repeats, and it lacks Lysine 
residues and a PDZ binding domain in its ICD (see Discussion). 
To analyze which of these structural differences contribute to 
the functional divergence, we generated various C-terminally 
fl  ag-tagged chimeric Dll1-Dll3 cDNAs (Fig. 5 A) and cell lines 
stably expressing the chimeric proteins. Cell lines were ana-
lyzed for expression by Western blotting to identify clones ex-
pressing similar levels of different protein variants for further 
analyses. Chimeric ligands A–H but not DLL3 (see the follow-
ing section) were readily detected on the cell surface after sur-
face biotinylation, followed by immunoprecipitation and Western 
blotting (Fig. 5 B).
A chimeric ligand, in which the N-terminal portion of 
DLL3, including the DSL domain, was replaced by the corre-
sponding DLL1 sequence (Fig. 5 A, construct A) did not acti-
vate Notch neither in vitro (Fig. 5 C) nor in D. melanogaster 
wing discs (Fig. 4, J and K), indicating that the N terminus and 
DSL domain of DLL1 are not suffi  cient to confer Notch activat-
ing properties on DLL3. The inability of construct A to activate 
Notch could be due to the presence of the ICD of DLL3, or spe-
cifi  c EGF repeats, or both. To distinguish between these possi-
bilities, we tested a chimeric ligand consisting of the extracellular 
domain of DLL1 and the transmembrane domain (TM) and ICD 
of DLL3 (Fig. 5 A, construct B). This construct also did not 
activate Notch (Fig. 5 C), indicating that the ICD of DLL1 is 
essential, which was further supported by the inability of a DLL1 
variant that lacked the ICD (Fig. 5 A, construct H) to activate 
Notch (Fig. 5 C). To further defi  ne features in the extracellular 
domain of DLL1 that are essential for Notch activation, we 
tested various constructs that contained the ICD of DLL1 and 
combinations of portions of the extracellular domains of DLL1 
and DLL3.
EGF repeats 3–6 of DLL3 closely resemble repeats 5–8 in 
DLL1. We fi  rst tested a DLL1 variant that had EGF repeats 5–8 
replaced by EGF 3–6 from DLL3. This ligand (Fig. 5 A, con-
struct C) effectively activated Notch in vitro (Fig. 5 C) and in 
D. melanogaster wing discs (Fig. 4, L and M), indicating that the 
four proximal EGF repeats of DLL1 and DLL3 are functionally 
equivalent. We thus focused on the distal EGF repeats for further 
analyses. A DLL1 version that contained EGF repeats 1 and 2 
from DLL3 (Fig. 5 A, construct D) did not activate, suggesting 
that either the spacing of DLL3 EGF repeats or their sequence is 
important. To distinguish these possibilities, we inserted the 
DLL3 spacer sequence between EGF repeat 1 and 2 of DLL1 
(Fig. 5 A, construct E) or deleted the spacer between EGF repeat 
1 and 2 of DLL3 (Fig. 5 A, construct F). Both ligands did not 
activate Notch, indicating that both spacing and sequence of the 
fi  rst EGF repeats are critical for DLL1 function. To test whether 
the DSL domain and distal two EGF repeats of DLL1 are suffi  -
cient to activate Notch, we replaced the six proximal EGF repeats 
of DLL1 by the EGF repeats of DLL3 (Fig. 5 A, construct G). 
This ligand activated Notch in vitro, though not at maximal levels 
(Fig. 5 C), and in D. melanogaster wing discs (Fig. 4, N and O), 
suggesting that EGF repeats 1 and 2 of DLL1, or the spacing 
between these EGF repeats, are also essential for full activity.
DLL3 is predominantly located intracellularly
In the course of analyzing chimeric ligands, we also generated 
CHO cell lines stably expressing DLL3. Surprisingly, it proved 
Figure 4.  Activity of Dll1 and Dll3 in D. mela-
nogaster wing discs. Expression of D. melano-
gaster Dl and vertebrate orthologues with 
ptcGal4 in the wing imaginal discs. (A) Ex-
pression of Wg and ptcGal4 in a wing ima-
ginal disc of the late third larval instar. Wg 
(red) is induced along the dorsoventral (d-v) 
compartment boundary by Notch signaling. 
Expression of UAS GFP (green) reveals the 
stripe-like expression domain of ptcGal4, 
which runs perpendicular to the Wg domain at 
the anterior side of the A-P compartment bor-
der. Expression within the ptcGal4 domain in-
creases toward the posterior (right). (B and C) 
Ectopic Wg activation along the A-P boundary 
(arrows) induced by ectopic expression of 
D. melanogaster Dl. Two ectopic stripes of Wg 
expression are induced (arrows). The broader, 
anterior-located stripe is in the region of low 
Dl expression. The second thinner is induced in 
cells adjacent to the ptc domain. In the region 
with highest expression of Dl, expression of 
Wg is not induced because of the cis-inhibitory 
effect of Dl at high levels of expression. Note 
that high levels of Dl also suppress Notch activ-
ity at the dorsoventral boundary as indicated by down-regulation of Wg (arrowheads). Expression of Dll1ﬂ  ag (D and E) or Dll4ﬂ  ag (F and G) along the A-P 
boundary activates ectopic expression of Wg (arrows) in a pattern similar to Dl. However, the cis-inhibitory effect is weaker than in the case of Dl. (H and I) 
Expression of Dll3ﬂ  ag has no effect on the activity of the Notch pathway in D. melanogaster. In addition, endogenous expression of Wg along the dorso-
ventral border is not affected (arrowheads). (J and K) Expression of construct A (Dll1/Dll3 chimera; Fig. 5) does not activate the Notch pathway in D. mela-
nogaster. (L and M) Ectopic Wg activation along the A-P wing border (arrow) by ectopic expression of construct C (Dll1/Dll3 chimera; Fig. 5). In the regions 
with highest expression, construct C slightly suppresses Notch activity, as indicated by the slight down-regulation of Wg in its normal expression domain 
(arrowheads). (N and O) Ectopic Wg activation along the A-P wing border (arrows) by ectopic expression of construct G (Dll1/Dll3 chimera; Fig. 5). In 
the regions with highest expression, construct G slightly suppresses Notch activity, as indicated by the slight down-regulation of Wg in its normal expression 
domain (arrowheads). Note that construct C, as well as construct G, signals to cells adjacent to the posterior domain boundary (L–O, arrows).JCB • VOLUME 178 • NUMBER 3 • 2007  470
diffi  cult to obtain cells that expressed DLL3 effi  ciently on the 
surface, as determined by surface biotinylation and subsequent 
immunoprecipitation and Western blotting, and several clones ex-
pressing DLL3 had only minor amounts on the surface. Even when 
DLL3 was detected on the surface, relative amounts of DLL3 
were always signifi  cantly lower than those of DLL1 (Fig. 6 A, 
compare lane a with lanes b and c). Likewise, we detected no or 
minor amounts of biotinylated DLL3 on the cell surface of C2C12, 
HEK293, and CHO cells after transient transfection, although DLL3 
protein was readily detected in cell lysates (Fig. S1, available 
at http://www.jcb.org/cgi/content/full/jcb.200702009/DC1). 
To further analyze the apparent difference in surface presenta-
tion, we transiently expressed DLL3 in cells stably expressing 
DLL1, and vice versa, and analyzed the surface expression of 
both proteins. In either case, DLL1 was readily detected on 
the surface, whereas DLL3 was not or only at minor amounts 
(Fig. 6 A, lanes d–i). Consistent with the surface biotinylation 
data, DLL1 was readily detected by immunohistochemistry on the 
cell surface of CHO cells stably expressing DLL1 (Fig. 6 B a), as 
well as on the surface of transiently transfected CHO, HEK293, 
and C2C12 cells (Fig. S2, a–d; and not depicted), and on the 
apical surface of D. melanogaster wing disc cells (Fig. 6 B, i and j), 
although surface expression patterns were variable, and DLL1 
protein was also detected in vesicular structures in the cyto-
plasm. In contrast, DLL3 staining was mostly perinuclear (Fig. 
6 B b and Fig. S2, e–h). In the perinuclear region, DLL3 
co  localized with GM130, a marker for the cis-Golgi network 
(Fig. S2, i–k). When coexpressed, DLL1 and DLL3 colocalized 
in perinuclear structures but essentially not at the membrane 
(Fig. 6 B e and Fig. S2, n and q). Collectively, our data suggested 
that in cells expressing DLL1 and/or DLL3, DLL1 is largely on 
the cell surface and DLL3 is largely intracellular, including the 
Golgi apparatus. Similarly, in embryos in PSM cells, endog-
enous DLL1 was present on the surface and colocalized with 
membrane proteins detected by an anti-pancadherin antibody 
(Fig. 6 B, k–m), in addition to some intracellular DLL1 that 
colocalized mainly with GM130 (Fig. 6 B, q–s). Importantly, 
endogenous DLL3 was not detected on the membrane of PSM 
cells (Fig. 6 B, n–p) but in intracellular punctae largely over-
lapping with GM130 (Fig. 6 B, t–v), indicating that the localiza-
tion of DLL3 in the Golgi network occurs under physiological 
conditions. Both DSL proteins colocalized in some areas but 
were otherwise essentially nonoverlapping (Fig. S2, r–t). We also 
observed in PSM cells colocalization of DLL1 but not DLL3 
with clathrin heavy chain that marks clathrin-coated vesicles and 
early endosomes (Fig. S2, u–z), further supporting differential 
subcellular localization of DLL1 and DLL3. Collectively, our 
data suggest that in vivo DLL3 accumulates in the Golgi network 
and only minor amounts, if any, are present on the surface of 
PSM cells.
Protein domains affecting 
subcellular localization
The surface biotinylation results suggested that chimeric lig-
ands differ with respect to their propensity to localize to the 
surface. To analyze in more detail how different portions of DLL1 
and DLL3 affect the distribution of stably overexpressed chime-
ric ligands in the cell, we studied their localization on the cellu-
lar level by indirect immunofl  uorescence (Fig. 7). Chimeric 
ligands that contained the TM and ICD (TM-ICD) of DLL1 and 
at least the DLL1 N-terminal portion including the DSL domain 
fused to extracellular DLL3 sequences were detected on the cell 
surface, in addition to variable intracellular expression (Fig. 7 B, 
c–e). In contrast, the DLL1 N terminus alone (chimera J) was 
not suffi  cient to direct detectable surface expression (Fig. 7 B f), 
similar to the extracellular domain of DLL3 fused to DLL1 
TM-ICD, (chimera K; Fig. 7 B g). Because DLL1 lacking the ICD 
was also detected predominantly on the surface (Fig. 7 B b), 
Figure 5.  Analysis of Dll1-Dll3 chimeric ligands. (A) Schematic overview 
of wild-type DLL1 and DLL3 and chimeric constructs used to generate stably 
expressing CHO cell lines. DLL1 protein is shown in black and DLL3 in red. 
Numbers indicate the amino acid residue numbers. DSL, DSL domain; 
E1–E8, EGF-like repeats; the ﬂ  ag tag is indicated by gray ovals and the HA 
tag in construct H by a black oval. Corresponding EGF repeats of DLL1 
and DLL3 are connected by black lines. (B) Western blot analysis of cell ly-
sates (input) and streptavidin immunoprecipitated protein after surface bio-
tinylation (IP). CHO cells stably expressing chimeric ligands show similar 
(input A and B) or even more (input C–H) expression compared with DLL1-
expressing cells. All chimeric ligands are present on the cell surface (IP), 
chimeric ligands A, C, and G at lower levels and chimeric ligands B, D–F, 
and H at similar or even higher levels compared with DLL1. (C) Notch 
transactivation assays. CHO cells stably expressing DLL1 and chimeric 
ligands as shown in panel A were cocultivated with Notch1-HeLa cells 
transfected with the (RbpJ)6-luciferase reporter gene. Luciferase activity 
(percentage of activation) of chimeric ligands A–H was measured against 
negative (CHO wild-type cells) and positive (CHO-Dll1 cells) controls set to 
0 and 100% relative activation, respectively. Four cocultivations were per-
formed per construct and analyzed in two independent experiments each, 
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the DSL domain of DLL1 appears to be necessary to direct sur-
face expression of these chimeric ligands. A chimera containing 
the DLL1 extracellular domain juxtaposed to the DLL3 TM-ICD 
(chimera B) was predominantly on the surface, although not 
evenly distributed (Fig. 7 B h). Chimeras that contained the 
DLL1 N-terminal portion, including the DSL domain, and the 
DLL3 TM in the context of juxtaposed DLL3 intra- and extra-
cellular sequences were found predominantly intracellular     
(Fig. 7 B, i and j). In contrast to cells expressing DLL1, or con-
struct H or B, that consistently showed clear expression on the 
surface, surface presentation of most chimeric ligands was vari-
able and not detected in all expressing cells. As expected, a chi-
mera containing the DLL1 N-terminal portion without the DSL 
domain fused to DLL3 (chimera M) showed no detectable mem-
brane localization (Fig. 7 B k). Collectively, it appears that the 
DLL3 TM and adjacent extra- and intracellular sequences con-
tribute to retention of chimeric ligands in intracellular compart-
ments and localization of DLL3 in the Golgi network.
Discussion
This study addresses the biochemical and functional equiva-
lence of the Notch ligands DLL1 and DLL3 and shows that, under 
physiological conditions, in vivo DLL3 cannot substitute for 
DLL1 in mice, and DLL1 (and DLL4, but not DLL3) can func-
tion as an activating Notch ligand in mice and D. melanogaster. 
Figure 6.  Localization of DLL1 and DLL3 proteins. 
(A) Western blot analysis of cell lysates (input) and 
streptavidin-immunoprecipitated protein after surface bio-
tinylation (IP). CHO cells stably expressing DLL3 (b and c) at 
amounts similar to cells expressing DLL1 (a) present signiﬁ  -
cantly less DLL3 on the surface. L cells (mouse ﬁ  broblast 
cell line) coexpressing DLL3ﬂ  ag at signiﬁ  cantly higher lev-
els than DLL1HA (compare input lanes d and g) present 
DLL1 efﬁ  ciently on the surface but not DLL3 (compare IP 
lanes d and g). CHO cells coexpressing DLL3HA and DLL-
1ﬂ  ag (compare input lanes e and f with h and i) present 
DLL1 efﬁ  ciently on the surface but DLL3 only in trace 
amounts (compare IP lanes e and f with h and i). (B) Detec-
tion of DLL1 and DLL3 by immunoﬂ  uorescence. (a–e) Lo-
calization of DLL1 and DLL3 in overexpressing CHO cells. 
CHO cells expressing DLL1 (a and c) show a clear cell 
surface staining, whereas DLL3 (b and d) is detected al-
most exclusively inside the cell. DLL1 and DLL3 colocalize 
only in some vesicular structures (e, arrowheads) but not 
signiﬁ  cantly at the membrane. (f–j) Localization of DLL1 
and DLL3 in D. melanogaster wing disc cells. (f) Overview 
of a wing disc stained for the apical cell membrane marker 
aPKC and DLL3ﬂ  ag, and Hoechst staining to visualize 
nuclei. (g and h) Confocal images of two opposed apical 
cell membranes (red) of an epithelial fold in panel f. DLL3 is 
found in intracellular granules or vesicles. (i and j) Confocal 
images of two opposed apical cell membranes (red) of a 
wing disc stained for aPKC and DLL1ﬂ  ag. DLL1 outlines cell 
membranes and colocalizes at the apical membrane with 
aPKC (j, arrowheads). (k–v) Immunoﬂ  uorescent detection of 
DLL1 and DLL3 in PSM cells of E9.5 embryos. Endogenous 
DLL1 is present at the surface (k) and colocalizes with the 
membrane (m) and in vesicular structures with the cis-Golgi 
marker GM130 (s). DLL3 does not localize to the membrane 
(n) and does not colocalize with anti-pancadherin staining 
(p) but is detected in vesicular structures in the cytoplasm (t), 
mostly overlapping with GM130 (v). Bars, 10 μm. JCB • VOLUME 178 • NUMBER 3 • 2007  472
In addition, we have defi  ned regions in DLL1 that are essen  tial 
for its function as activating Notch ligand. In contrast to the 
reported potent inhibitory functions of DLL3 overexpressed 
in vitro, and in Xenopus embryos (Ladi et al., 2005), increased 
ratios of Dll3/Dll1 in mouse embryos or overexpression in 
D. melanogaster did not provide evidence for antagonism be-
tween Dll1 (or Dl or Ser) and Dll3. In addition, our data show 
an unanticipated accumulation of DLL3 in the Golgi network 
that war  rants further investigation of potential intracellular func-
tions of DLL3.
DLL3 cannot substitute for DLL1 in vivo
The rescue of Dll3
pu mutant phenotype by Dll3 expressed from 
the Dll1 locus demonstrated that suffi  cient amounts of func-
tional DLL3 protein are generated from the knockin allele. 
However, homozygous Dll1
Dll3HAki or Dll1
Dll3ki embryos were 
virtually indistinguishable from Dll1-null mutant embryos (Fig. 1), 
indicating that DLL3 cannot substitute for DLL1 and acti-
vate Notch in vivo. Given that <25% of normal Dll1 levels are 
suffi  cient to signifi  cantly improve the phenotype of Dll1-null 
mutants, and that DLL3 was not found on the cell surface in ap-
preciable amounts (see below), it is highly unlikely that DLL3 
has the ability to activate Notch under physiological conditions. 
Our results provide defi  nitive proof that the DLL1 and DLL3 
proteins are functionally highly diverged and are biochemically 
not equivalent in vivo and support recent in vitro data showing 
that DLL3 cannot bind to and activate Notch in trans (Ladi 
et al., 2005).
Regions in DLL1 required for activation 
of Notch
The DLL1 and DLL3 proteins differ in various respects. The 
DSL domain, which is essential for ligand binding to Notch 
(Shimizu et al., 1999), is highly divergent in DLL3 and lacks 
a YY and a GWXG motif that is present in the DSL domains of 
other Notch ligands in various species. These features appear to 
be essential, as mutation of either of these motifs abolishes Dll1 
function (unpublished data). However, the transfer of the DLL1 
N terminus and DSL domain to the DLL3 EGF repeats (Fig. 5, 
construct A) was not suffi  cient to confer activating properties to 
DLL3, which was also reported by Ladi et al. (2005), indicating 
that other portions of DLL1 are essential for its activating prop-
erties. The C-terminal amino acid sequence of DLL1 and Jag-
ged1, but not DLL3, constitutes a potential PDZ ligand, which 
was recently shown to be required for Jagged1-mediated cellu-
lar transformation (Ascano et al., 2003). The ICD of DLL3 also 
lacks lysine residues that are required for ubiquitin conjugation 
and ubiquitin-dependent processing and internalization of DLL1 
(Pavlopoulos et al., 2001; Barsi et al., 2005; Koo et al., 2005; 
Pitsouli and Delidakis, 2005). The exchange of the TM-ICD 
of DLL1 with the corresponding region from DLL3 (Fig. 5, 
construct B) abolished the ability to activate Notch, indicating 
Figure 7.  Localization of chimeric DLL1 and DLL3 proteins. (A) Schematic representation of chimeric proteins containing the ICD of DLL1 (left) or DLL3 (right) 
arranged according to the extent of extracellular DLL1 sequences (top to bottom). Gray parts and red parts indicate DLL1 and DLL3 sequences, respectively. 
White ﬁ  lling indicates DSL domains, light gray or red shading indicates TMs, and ﬁ  lled boxes indicate EGF repeats. (B) Confocal images of CHO cells sta-
bly expressing chimeric ligands and stained by indirect immunoﬂ  uorescence. Similar to DLL1 (a) and DLL1 lacking the ICD (b), chimeric ligands that con-
tained the TM-ICD of DLL1 and the DLL1 N-terminal portion including the DSL domain were detected on the cell surface (c–e), in addition to some variable 
intracellular expression. Presence of the DLL1 N terminus alone was not sufﬁ  cient to direct detectable surface expression (f), similar to the extracellular 
domain of DLL3 fused to DLL1 TM-ICD (g). Surface presentation of a chimera containing the DLL1 extracellular domain juxtaposed to the DLL3 TM-ICD (h). 
Chimeras that contain the DLL1 N-terminal portion including the DSL domain, and the DLL3 TM in the context of juxtaposed DLL3 intra- and extracellular 
sequences were retained intracellularly (i and j). Intracellular localization of DLL3 with the N terminus replaced by the corresponding DLL1 sequence, and 
of DLL3, respectively (k and l). A–C, G, and H refer to chimeras shown in Fig. 5 A and I–M to additional ones. Chimera H (b) was detected with anti-DLL1 
and all other chimeras with anti-ﬂ  ag antibodies. Bar, 10 μm.NONEQUIVALENCE OF DLL1 AND DLL3 • GEFFERS ET AL. 473
that properties of this region are critical for DLL1 function. The 
C-terminal tag is likely to interfere with binding to PDZ binding 
proteins. Because C-terminal tagging of the full-length DLL1 
protein does not interfere with Notch activation in trans in cell 
culture experiments and fl  ies, PDZ binding is unlikely to be re-
quired for Notch activation. This is supported by the observa-
tion that a zebrafi  sh DeltaD variant that cannot interact with 
PDZ domains functions normally as a Notch ligand (Wright 
et al., 2004). Thus, the inability of construct B to activate Notch 
might be due to loss of ubiquitin-dependent processing (Le Borgne 
et al., 2005) or loss of other as-yet-undefi  ned modifi  cations 
(Ilagan and Kopan, 2007) that require the presence of the ICD. 
This is further supported by the results obtained with construct 
H, which indicate that mere presentation of the extracellular 
domain of DLL1 on the surface is not suffi  cient for Notch ac-
tivation in trans. Activating properties of DLL1 were maintained 
when the N-terminal region of DLL1, including EGF repeats 
1 and 2, was fused to EGF repeats 1–6 from DLL3, followed by 
the TM-ICD of DLL1 (construct G). This was not true of con-
structs that contained DLL3 EGF repeats 1 and 2 with or with-
out correct spacing (constructs D and F) or DLL1 EGF repeats 
1 and 2 with changed spacing (construct E). This indicates that 
EGF repeats 1 and 2 of DLL1 have specifi  c properties that are 
not present in the corresponding EGF repeats of DLL3 and is 
consistent with a requirement for the DSL domain and EGF 
repeats 1 and 2 in Jagged1 for Notch binding in vitro (Shimizu 
et al., 1999). Collectively, DLL3 has acquired several alterations, 
each of which individually appears to be suffi  cient to abolish its 
function as an activating Notch ligand.
Is DLL3 an intracellular component 
of the Notch pathway?
Surprisingly, in contrast to DLL1, we found that the majority of 
DLL3 overexpressed in cell lines resided within the cell and 
was virtually absent from the cell surface. The same was true 
for DLL3 expressed in D. melanogaster wing disc cells and for 
endogenous DLL3 expressed in the PSM. Thus, DLL1 and DLL3 
appear to differ signifi  cantly in their propensity to localize to 
the cell membrane. This is further supported by the distinct sub-
cellular localization of DLL1/DLL3 chimeras depending on 
the presence of particular regions of DLL1 and DLL3 (Fig. 7). 
The transmembrane region of DLL3, together with fl  anking 
sequences on either side, appears to prevent effi  cient surface 
presentation and might be important for Golgi retention, as has 
been found for other Golgi-retained proteins, such as glycosyl-
transferases (Colley, 1997). The presence of a retention signal 
could explain why signifi  cant amounts of DLL3 can only be 
detected on the surface when DLL3 is highly overexpressed. 
In this context, it is worth mentioning that it is not clear if the 
majority of DLL3 was located intracellularly in the study of Ladi 
et al. (2005), as they did not report immunohistochemical data. 
Importantly, endogenous DLL3, in contrast to DLL1, did not 
colocalize with a membrane marker in PSM cells but was found 
to colocalize with GM130. Thus, under physiological condi-
tions, the majority of DLL3 appears to reside in the Golgi ap-
paratus (Fig. 6), suggesting that it can exert its function inside 
the cell. However, we cannot exclude the possibility that minor 
amounts of DLL3 act on the cell surface. Binding of DLL3 to 
Notch in cis (when coexpressed in the same cells), but not in 
trans (when expressed in adjacent cells; Ladi et al., 2005) would 
also be consistent with Notch interaction and DLL3 function 
inside the cell.
Is DLL3 an antagonist of DLL1 in vivo?
It has been suggested that DLL3 acts as a Notch antagonist dur-
ing somitogenesis (Ladi et al., 2005). This is because in vitro 
DLL3 did not activate Notch in trans, but rather inhibited Notch 
signaling when expressed in the same cell as Notch. In addition, 
overexpression of Dll3 in Xenopus embryos enhanced neu-
ronal differentiation. Cell-autonomous inhibition and intra-
cellular association with Notch is also a property of ligands that 
physiologically activate Notch in trans when they are over-
expressed in cis (Doherty et al., 1996; Henrique et al., 1997; Klein 
et al., 1997; Sakamoto et al., 2002; Itoh et al., 2003). Thus, in-
hibition of Notch by overexpressed DLL3 in cis is not neces-
sarily indicative of an antagonistic function in vivo, a notion 
that is supported by our results. Heterozygous mice that carry 
the Dll1
Dll3HAki or Dll1
Dll3ki alleles (i.e., mice that overexpress Dll3 
and simultaneously have only one copy of Dll1 were indistin-
guishable from heterozygous Dll1-null mice). In these mice, 
Dll3 is also expressed ectopically in the posterior somite com-
partment with no apparent effect on Dll1 function in somite pat-
terning. Also, the phenotypes of embryos with further reduced 
Dll1 levels with or without additional Dll3 were virtually identical. 
Thus, reducing the activating ligand DLL1 and simultane-
ously increasing DLL3 did not lead to observable enhancements 
of Dll1 phenotypes, suggesting that overexpression at physio-
logical levels does not signifi  cantly impair Notch activation. 
If DLL3 inhibits Notch in vivo, loss of Dll3 function should lead 
to increased Notch activity and, thus, up-regulation of Notch 
target genes. However, known Notch1 targets, like Nrarp or 
Hes5, are either not signifi  cantly deregulated or down-regulated 
in Dll3 mutants (Krebs et al., 2001; Dunwoodie et al., 2002), 
which suggests a stimulatory function of DLL3 in Notch signaling. 
Also, we did not observe evidence for increased NICD produc-
tion in the PSM. This implies that, if DLL3 acts to antagonize 
DLL1, this effect would have to occur downstream of NICD 
formation (i.e., Notch activation). A recent study indicates that 
in order for cis inhibition to occur, the ligands have to come to 
the cell surface (Glittenberg et al., 2006). However, we found 
that the vast majority of DLL3 resides in the Golgi apparatus. 
This fi  nding further argues against an inhibitory function of 
DLL3, at least by a mechanism similar to the other ligands. Also, 
the similarity of the Dll3- and Lfng-null phenotypes does not 
allow one to conclude that DLL3 acts as an inhibitor similar to 
LFNG, as loss of Lfng function and overexpression of Lfng cause 
virtually identical phenotypes (Serth et al., 2003).
Collectively, our in vivo data unambiguously demonstrate 
that DLL1 and DLL3 have distinct functions under physio-
logical conditions in vivo and open the possibility that these 
proteins function at different sites in the cell. In addition, our 
in vivo data do not support an antagonistic function of DLL1 
and DLL3 in PSM cells and point toward a potential, thus far 
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Materials and methods
Generation of Dll3 knockin mice
The Dll3 ORF (with or without a C-terminal HA tag) was fused to a genomic 
Dll1 SacI–EcoRI fragment containing part of exons 9, 10, and 11. A PGK-
neomycin expression cassette ﬂ  anked by loxP sites was introduced 3′ to 
the Dll3-Dll1 fusion. A 4.6-kb BamHI–KpnI fragment of Dll1 genomic DNA 
upstream of the ATG fused in frame to Dll3, and  3 kb of Dll1 genomic 
DNA downstream of the SalI site in exon 2 were included as regions of 
5′ and 3′ homology, respectively. A diphtheria toxin A expression cassette 
was cloned upstream and downstream of the homology arms, respectively. 
The analogous Dll1ki targeting vector was cloned as previously described 
(Schuster-Gossler et al., 2007). Linearized vector DNA was electroporated 
into 129Sv/ImJ embryonic stem cells and selected as described previously 
(Abdelkhalek, 2004). Correctly targeted clones were identiﬁ  ed by PCR 
using primers derived from the neo sequence (T  G  T  C  A  C  G  T  C  C  T  G  C  A  C  -
G  A  C  G  ) and genomic sequences downstream of the targeting vector 
(G  G  T  A  T  C  G  G  A  T  G  C  A  C  T  C  A  T  C  G  C  ). PCR-positive clones were veriﬁ  ed  by 
Southern blot analysis using external probes located 3′ and 5′ to the re-
gions of homology in the vector and used to generate chimeric mice. The 
neo cassette was removed in the female germ line using ZP3::Cre mice 
(de Vries et al., 2000; backcross generation N6 to 129Sv/ImJ).
Genotyping of mice and embryos
Genomic DNA isolated from tail biopsies or yolk sacs was genotyped by 
PCR. Used primers were as follows: for Dll1 wild-type allele, Dll1F2 (C  T  G  A  A  G-
C  G  A  C  C  T  G  G  C  C  C  T  G  A  T  A  G  C  A  C  ) and Dll1R1 (G G  A  G  T  C  G  A  C  A  C  C  C  A  G  C  A  C  T-
G  G  C  G  ; 425 bp); for Dll1
lacZ allele, Melta38 (A T  C  C  C  T  G  G  G  T  C  T  T  T  G  A  A  G  A  A  G  ) 
and LacZ1/Dll1ko (C  A  A  A  T  T  C  A  G  A  C  G  G  C  A  A  A  C  ; 578bp); for Dll1
Dll3HA, 
Dll1
Dll3, and Dll1
Dll1 ∆neo alleles, EGF-neoFOR (A T  G  G  A  C  A  G  C  A  T  T  T  C  C  T  C  C  T  G-
C  C  T  C  ) and EGF-neoREV (G  C  C  A  G  T  C  A  G  T  T  C  C  C  A  G  T  A  A  G  A  A  G  T  C  ; 280 bp); 
for Dll1
Dll1+neo allele, neoF (T  G  G  A  T  G  T  G  G  A  A  T  G  T  G  T  G  C  G  A  G  ) and Dll1h3′B6 
(A  A  G  G  G  G  A  G  A  A  G  A  T  G  C  T  T  G  A  T  A  A  C  C  ); for Dll3
pu allele, Dll3pu1 (A C  G  A  G  C-
G  T  C  C  C  G  G  T  C  T  A  T  A  C  ) and Dll3pu2 (A  G  G  T  G  G  A  G  G  T  T  G  G  A  C  T  C  A  C  C  ). After 
ampliﬁ  cation, PCR products were cleaved with HaeIII and separated on 3% 
agarose gels (Dll3
pu/pu, 100 bp; and wild type, 65 bp).
Skeletal preparations of E18.5 embryos
E18.5 embryos were eviscerated and skinned, and skeletons were stained 
as described previously (Serth et al., 2003) with slightly longer incubation 
periods. Stained skeletons were stored and photographed in ethanol/
glycerol (1:1) using a microscope (M420; Leica) with Apozoom 1:6 and 
Photo  grab-300Z version 2.0 software (Fujiﬂ  m).
Whole-mount in situ hybridization
Whole-mount in situ hybridization was performed following a standard pro-
cedure with digoxygenin-labeled antisense riboprobes (Wilkinson, 1992) 
with minor modiﬁ  cations. Pictures were taken using the Leica M420 micro-
scope with Apozoom 1:6 and Photograb-300Z version 2.0 software.
Whole-mount immunohistochemistry
E10.5 embryos were collected in PBS, immediately ﬁ   xed in MeOH/
DMSO/30% H2O2 (1:1:1) for 1 h on ice, and washed 3× 10 min and 2× 
1 h in 50 mM NH4Cl at room temperature, followed by an incubation in 
TS-PBS (PBS, 10% FCS, and 1% Triton X-100) for 3× 10 min and 2× 1 h 
at 4°C. Embryos were then successively incubated with anti–cleaved 
Notch1 antibody (Val1744; Cell Signaling), biotinylated anti-rabbit anti-
body (Vector Laboratories), and streptavidin-HRP (NEL750; Perkin-Elmer) at 
a dilution of 1:100 in TS-PBS overnight at 4°C, respectively. Between anti-
body incubations, embryos were washed repeatedly with TS-PBS during 
the day at room temperature. For the color reaction, embryos were incu-
bated 2× 10 min in solution A (100 mM Tris-HCl, pH 7.5, 0.1% Triton 
X-100, and 0.04% 4 Chloro-1 naphthol), 2× 5 min and 1× 10 min in 
solution B (solution A without Triton X-100), 1× 10 min in solution C 
(2 parts of 0.125% 4 Chloro-1 naphtol in 100% ethanol mixed with 3 parts 
of distilled water) followed by incubation in solution D (solution C with 
0.006% H2O2), and stopped with 4% paraformaldehyde. Pictures were 
taken using the Leica M420 microscope with Apozoom 1:6 and Photo-
grab-300Z version 2.0 software.
Whole-mount immunoﬂ  uorescence
Embryos were dissected at E9.5, ﬁ   xed in 4% paraformaldehyde over-
night at 4°C, and stored in methanol at −20°C. Rehydrated embryos were 
washed three times in antigen unmasking solution (Vector Laboratories), 
heated to 100°C for 10 min, and allowed to cool to room temperature. 
Embryos were washed in water and cracked for 8 min in 100% ace-
tone prechilled to −20°C and then rehydrated in water. Embryos were 
blocked overnight in 1% BSA dissolved in PBS-TR (PBS containing 0.1% 
Triton X-100) at 4°C. Primary antibodies diluted in block were incubated 
with embryos at 4°C for 2–3 d with gentle agitation. Embryos were 
washed six times in PBS-TR for 30 min each and then reblocked for 1–2 h 
at room temperature. Fluorochrome-conjugated secondary antibodies (Jackson 
ImmunoResearch Laboratories and Invitrogen) were diluted in block 
and incubated with embryos at 4°C overnight with gentle agitation. The 
embryos were washed six times in PBS-TR for 30 min each, cleared by 
successive 10-min washes in 25% glycerol, 50% glycerol, and 70% 
glycerol. The posterior third of the embryos was dissected and ﬂ  at-mounted 
sagittally in ProLong Gold antifade (Invitrogen). Fluorochromes used were 
Texas red, Alexa Fluor 488, FITC, Cy2, Cy3, and Cy5. Labeled cells were 
analyzed at room temperature by confocal laser-scanning microscopy 
using the LSM 510 Meta (Carl Zeiss MicroImaging, Inc.) connected to 
the inverted microscope (Axiovert 200M; Carl Zeiss MicroImaging, Inc.) 
with a Plan Apochromat 63×/1.4 oil differential interference contrast 
objective or using a TCS SP confocal microscope (Leica) using a PL APO 
100×/1.4 objective (Leica). For image acquisition, LSM 510 and Leica 
Confocal Software v2.5 were used, respectively. For images acquired 
on the TCS SP confocal microscope, ImageJ was used to add scale bars. 
Pictures were processed and assembled using Photoshop and Illustrator 
CS (Adobe).
Immunoﬂ  uorescence staining of cells
Immunocytochemistry was performed as described by Dahlqvist et al. 
(2003) and visualized at room temperature using a TCS SP confocal 
microscope or as follows. Cells grown on gelatin-coated coverslips were 
rinsed twice with PBS and ﬁ  xed with methanol for 10 min at 4°C. After 
three washes with PBS, the cells were blocked with 5% donkey serum in 
PBS for 30 min at room temperature. Cells were incubated with the pri-
mary antibody for 1 h at room temperature and, after three washes with 
PBS, with the ﬂ  uorochrome-conjugated secondary antibody (Dianova; 
Invitrogen). After washing, the coverslips were mounted in Gel/Mount 
(Biomeda) or ProLong Gold antifade. Texas red–, FITC- and/or Alexa Fluor 
488–labeled cells were analyzed at room temperature by confocal laser-
scanning microscopy using the LSM 510 Meta connected to the inverted 
microscope Axiovert 200M with a Plan Apochromat 63×/1.4 oil differen-
tial interference contrast objective. Images were processed using LSM 510 
software. Pictures were processed and assembled using Photoshop and 
Illustrator CS.
Generation of expression constructs
The pTracer-Dll1Flag plasmid (a gift from S. Chiba, University of Tokyo, 
Tokyo, Japan) was modiﬁ   ed by inserting an IRES-neo cassette after the 
Dll1Flag ORF and served as a vector (pTracer-IRESneo) for expression of 
ﬂ  ag-tagged Dll1, Dll3, and chimeric ligands. Chimeric ligands were gener-
ated by conventional cloning methods. Junctions between the Dll1 and 
Dll3 sequences were created without changing the amino acid sequence 
by PCR mutagenesis using primers with a restriction site–containing 
overhang. In the case of the chimeric ligands D and E, two gene fragments 
containing a deletion or an insertion between EGF1 and -2 were syn-
thesized (GenScript). In addition, HA-tagged versions of Dll1 and Dll3 
were cloned into pTracer. The integrity of all constructs was veriﬁ  ed 
by sequencing. The junctions of Dll1 and Dll3 sequences in chimeric 
ligands are shown in Table S1 (available at http://www.jcb.org/cgi/
content/full/jcb.200702009/DC1).
Cell lines
L-Dl19 cells stably expressing rDll1HA were provided by G. Weinmaster 
(University of California, Los Angeles, Los Angeles, CA). CHO cells stably 
expressing Dll1-Dll3 chimeric ligands were generated by transfection of 
CHO cells using Jetpei (BIOMOL Research Laboratories, Inc.) according 
to the manufacturer’s instructions followed by neomycin selection. HeLa 
cells stably expressing Notch1 (Jarriault et al., 1998) were provided by 
A. Israël (Institut Pasteur, Paris, France).
Notch transactivation assay
HeLaN1 cells were transiently transfected with the Rbp-J luciferase reporter 
construct (Rbp)6-luc (Minoguchi et al., 1997) using Jetpei, following the 
manufacturer’s instructions. 10
6 transfected HeLaN1 cells were coculti-
vated on 6-well plates for 24 h with 10
6 CHO cells expressing ligands. Each 
CHO cell line was cocultivated four times in two independent experiments. 
Luciferase activity was measured using the Dual-Luciferase Reporter Assay NONEQUIVALENCE OF DLL1 AND DLL3 • GEFFERS ET AL. 475
System (Promega). Fireﬂ  y luciferase activity was normalized to cotrans-
fected Renilla luciferase activity (pRL-TK; Promega). Expression of chimeric 
ligands was veriﬁ  ed by Western blot analysis.
Cell surface biotinylation
Biotinylation-streptavidin pull down was performed essentially as described 
previously (Bush et al., 2001) or as described below. Cells were plated 
on 6-cm dishes and grown to conﬂ  uence. Plates were washed three times 
with cold PBS (137 mM NaCl, 2.7 mM KCl, 4.3 mM Na2HPO4, 1.4 mM 
KH2PO4, pH 7.3, 1 mM MgCl2, and 0.1 mM CaCl2) and placed on ice 
with 500 μl PBS. 10 μl Sulfo-NHS-LC-Biotin solution (5 mg/ml in 0.1 M 
sodium phosphate buffer, pH 7; Pierce Chemical Co.) were added three 
times in 10-min intervals. After 30 min, the biotin solution was aspirated, 
and the plates were washed once with 50 mM glycine in DME and incu-
bated for 30 min to quench the biotinylation reaction. Cells were washed 
twice with PBS and lysed with 400 μl RIPA (50 mM Tris/HCl, pH 8.0, 
150 mM NaCl, 1% NP-40, 0.5% DOC, and 0.1% SDS, supplemented with 
2.8 μg/ml aprotinin, 0.15 mM benzamidine, 2.5 μg/ml leupeptin, and 
2.5 μg/ml pepstatin A). Lysates were incubated for 30 min on ice and 
centrifuged for 10 min at 12,000 g to remove cellular debris. The biotinylated 
proteins were precipitated with streptavidin agarose (Sigma-Aldrich) over-
night at 4°C. The streptavidin agarose beads were washed three times with 
RIPA before resuspension in 2× sample buffer. Equivalent amounts of 
lysates and precipitates were subjected to SDS-PAGE and analyzed by 
Western blotting as described.
Antibodies
Antibodies used were as follows: HA (rat; clone 3F10; Boehringer), Wg 
(mouse; clone 4D4; Developmental Studies Hybridoma Bank), β-gal (rabbit, 
Cappel Research Products), Flag (mouse; clone M2; Sigma-Aldrich), 
PKCζ C20 (rabbit; Santa Cruz Biotechnology, Inc.), DLL1 (rabbit; Santa 
Cruz Biotechnology, Inc.), GM130 (mouse; clone 35; BD Biosciences), 
pancadherin (mouse; clone CH-19; Sigma-Aldrich), and clathrin heavy 
chain (BD Biosciences). Monoclonal antibodies against DLL1 were gener-
ated by immunization of rats with a peptide comprising amino acids 
524–540 (P  G  P  M  V  V  D  L  S  E  R  H  M  E  S  Q  G  ) of mouse DLL1 coupled to KLH or ov-
albumin (Peptide Specialty Laboratories) subcutaneously and intraperito-
neally with a mixture of 50 μg peptide-KLH, 5 nmol CPG oligonucleotide 
(Tib Molbiol), 500 μl PBS, and 500 μl IFAs. After a 6-wk interval, a ﬁ  nal 
boost without adjuvant was given 3 d before fusion of the rat spleen cells 
with the murine myeloma cell line P3X63-Ag8.653. Hybridoma supernatants 
were tested in ELISA using the speciﬁ  c peptide or an irrelevant peptide cou-
pled to ovalbumin. Peptide-speciﬁ   c mAbs were further characterized in 
Western blotting. mAb PGPM-1F9 reacted speciﬁ  cally with the DLL1 protein 
and was used for this study. In addition, guinea pig antisera were raised 
against the peptide C  S  P  E  H  G  Y  C  E  E  P  D  E   mapping to residues 222–234 of 
mouse DLL3 and afﬁ  nity puriﬁ  ed according to the manufacturer’s instructions 
(Peptide Specialty Laboratories).
Transgenic ﬂ  y lines
All constructs were cloned into the pUAST vector (Brand and Perrimon, 
1993) and used to generate transgenic ﬂ   ies by P-element–mediated 
transformation of D. melanogaster embryos (Rubin and Spradling, 1982). 
mDLL1-Flag was cloned through EcoRI + XbaI digestion from pTracerC-
MVDll1. mDLL3-Flag was cloned with EcoRI + NotI digestion from pTracer-
CMVDll3. pUAST–construct G plasmid was generated by a three-fragment 
ligation with the EcoRI–NotI and NotI–NotI fragments from pTracerCMV 
construct G into EcoRI + NotI digested pUAST vector. pUAST–construct C 
was cloned by an EcoRI + XbaI digestion from the pTracerCMVconstruct C. 
ratDLL1HA was cloned with XbaI from the pEF-Bos vector (pEF-Bos-rat-
DLL1HA vector was provided by G. Weinmaster). mDLL4-cDNA was re-
ceived from Amgen and cloned by EcoRI digestion from pCR2.1 (Invitrogen) 
into the pUAST vector. DLL4HA was generated by replacing the PshAI–KpnI 
fragment of the DLL4-cDNA with a 351-bp PCR product generated by using 
following oligonucleotides: A-5′-C  C  A  G  C  T  C  A  A  A  A  A  C  A  C  A  A  A  C  C  A  G  A  A  G  -3′ 
and B-5′ A  A  T  T  C  T  C  T  A  G  A  T  C  A  A  G  C  G  T  A  A  T  C  T  G  G  C  A  C  A  T  C  G  T  A  T  G  G  G  T  A  A  G-
C  T  A  C  C  T  C  T  G  T  G  G  C  A  A  T  C  A  C  A  C  A  -3′. Activity of the Notch signaling path-
way was revealed by monitoring the expression of Wg and the synthetic 
reporter construct Gbe+Su(H)m8-lacZ with antibody staining (Furriols 
and Bray, 2001). Immunostainings of wing imaginal discs were per-
formed as described by Jaekel and Klein (2006) using Alexa 488, 568, 
and 647 goat anti–mouse, Alexa 568 and 647 goat anti–rat, and Alexa 
568 and 647 goat anti–rabbit antibodies, respectively (Invitrogen). Discs 
were mounted in VectaShield H-1000 (Vector Laboratories), and ﬂ  uoro-
chromes were visualized using an Axioplan2 with ApoTome (Carl Zeiss 
MicroImaging, Inc.), 10×/0.30 Plan-NEOFLUAR, 25×/0.80 Imm Korr 
Plan-NEOFLUAR, and 63×/1.4 Oil Plan-Apochromat lenses (Carl Zeiss 
MicroImaging, Inc.) at 25°C. Pictures were taken with an AxioCam HRm 
camera (Carl Zeiss MicroImaging, Inc.) and AxioVision (versions 4.4 and 
4.6) software (Carl Zeiss MicroImaging, Inc.) and processed using Photo-
shop CS.
Online supplemental material
Fig. S1 shows surface biotinylation data of DLL3 expressed in HEK293, CHO, 
and C2C12 cells. Fig. S2 shows immunoﬂ  uorescence detection of DLL3 and 
DLL1 in cell lines and PSM cells. Table S1 shows the junctions of Dll1 and 
Dll3 sequences in chimeric ligands. Online supplemental material is avail-
able at http://www.jcb.org/cgi/content/full/jcb.200702009/DC1.
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